Three insights:
1. Generex will secure all assets of Pantheon including business operations, accounts receivable, inventory, contracts and real estate, among others.
2. The deal also states that the assets will be acquired on a debt free basis and in a non-cash transaction, as well as additional cash and stock consideration if sales and profit goals are met.
3. Pantheon will develop new products for submission to the FDA, which include cannulated surgical screws, surgical staples and its Hammertoe System.
“Our standard ‘all-in-one’ kits provide surgeons with an integrated kit of the implants, plates, screws and clips to perform 80 percent of their surgeries, and the kits can be customized for physician preference,” said Travis Bird, CEO of Pantheon. “We look forward to bringing our FDA-cleared line of surgical products to the network.”
More articles on devices:
Dr. Ben Walthall, former Johnson & Johnson director joins RenovaCare
Cerapedics expands Colorado HQ — 3 things to know
HSS acquires low-dose orthopedic imaging system — 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
